Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

How safe is aggressive statin therapy?

Robert M Guthrie1

  • 1The Ohio State University College of Medicine, Columbus, OH 43212, USA. guthrie.1@osu.edu

Progress in Cardiovascular Nursing
|September 8, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The use of dual antiplatelet therapy in high-risk patients with acute coronary syndromes.

The Journal of family practice·2016
Same author

Practice pearl: the effect of canagliflozin on HbA1c and blood pressure in patients with type 2 diabetes mellitus.

Postgraduate medicine·2015
Same author

Emerging data on the incidence of concussion in football practice at all levels of amateur play.

The Physician and sportsmedicine·2015
Same author

Clinical use of dipeptidyl peptidase-4 and sodium-glucose cotransporter 2 inhibitors in combination therapy for type 2 diabetes mellitus.

Postgraduate medicine·2015
Same author

Review of: effect of vitamin D supplementation on progression of knee pain and cartilage volume loss in patients with symptomatic osteoarthritis.

The Physician and sportsmedicine·2013
Same author

Sodium-glucose co-transporter 2 inhibitors and the potential for cardiovascular risk reduction in patients with type 2 diabetes mellitus.

Postgraduate medicine·2013

Aggressive low-density lipoprotein cholesterol goals are achievable with potent statins like atorvastatin, rosuvastatin, and simvastatin. Clinical data show benefits outweigh risks, despite provider and patient concerns about statin safety.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • National Cholesterol Education Program guidelines recommend lower low-density lipoprotein cholesterol (LDL-C) goals for cardiovascular disease (CVD) risk reduction.
  • Potent statins (atorvastatin, rosuvastatin, simvastatin) are key to achieving these aggressive LDL-C targets.

Purpose of the Study:

  • To address the perception gap regarding the safety of potent statins used for intensive LDL-C lowering.
  • To evaluate the risk-benefit profile of aggressive statin therapy in achieving guideline-recommended LDL-C goals.

Main Methods:

  • Review of clinical data and guidelines concerning statin therapy and LDL-C management.
  • Analysis of adverse event profiles for potent statins at high doses.

Main Results:

Related Experiment Videos

  • Aggressive LDL-C goals (<100 mg/dL or <70 mg/dL) are attainable with potent statins.
  • Clinical data indicate adverse events are infrequent, even with intensive statin therapy.
  • Potent statins demonstrate comparable safety profiles.

    • Conclusions:

    • The benefits of aggressive statin therapy in reducing cardiovascular events significantly outweigh potential adverse event risks.
    • Addressing provider and patient concerns about statin safety is crucial for optimal CVD risk management.